Insmed’s (INSM) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Insmed (NASDAQ:INSM) in a research note released on Friday morning,Benzinga reports. The brokerage currently has a $90.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Insmed’s Q1 2025 earnings at ($1.47) EPS, Q2 2025 earnings at ($1.42) EPS, Q3 2025 earnings at ($1.41) EPS and Q4 2025 earnings at ($1.22) EPS.

Several other research analysts also recently commented on INSM. Truist Financial reaffirmed a “buy” rating and issued a $105.00 price objective (up previously from $100.00) on shares of Insmed in a research note on Friday, November 1st. Wells Fargo & Company raised their target price on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 19th. Stifel Nicolaus upped their price target on shares of Insmed from $88.00 to $97.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. Morgan Stanley raised their price objective on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. One research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Insmed has a consensus rating of “Moderate Buy” and an average target price of $91.00.

Insmed Stock Performance

Shares of NASDAQ INSM opened at $81.06 on Friday. Insmed has a 12-month low of $21.92 and a 12-month high of $84.91. The firm has a market capitalization of $14.50 billion, a price-to-earnings ratio of -14.50 and a beta of 1.11. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The firm has a 50 day moving average of $74.29 and a 200 day moving average of $73.61.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The business had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. On average, research analysts anticipate that Insmed will post -4.56 earnings per share for the current year.

Insider Buying and Selling at Insmed

In related news, CEO William Lewis sold 18,750 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00. Following the completion of the transaction, the chief executive officer now owns 384,960 shares of the company’s stock, valued at approximately $26,885,606.40. This trade represents a 4.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Sara Bonstein sold 18,322 shares of Insmed stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $80.31, for a total value of $1,471,439.82. Following the completion of the transaction, the chief financial officer now owns 118,863 shares of the company’s stock, valued at approximately $9,545,887.53. This represents a 13.36 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 532,207 shares of company stock worth $41,400,465 in the last quarter. 4.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Insmed

Institutional investors have recently modified their holdings of the stock. Elequin Capital LP purchased a new stake in Insmed during the 4th quarter valued at $28,000. Steward Partners Investment Advisory LLC increased its position in Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 163 shares during the last quarter. V Square Quantitative Management LLC raised its stake in shares of Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 248 shares during the period. Spire Wealth Management bought a new stake in shares of Insmed in the 4th quarter worth about $47,000. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Insmed by 98.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 411 shares during the period.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.